Login to Your Account


Deal 'significantly derisks the whole program'
Shares in Bavarian Nordic A/S surged 35 percent Wednesday on news of a $975 million option and licensing deal with Bristol-Myers Squibb Co. involving its prostate cancer vaccine Prostvac. more »

Our Habitat for All Things Science
Blocking antioxidant pathways stops tumors in their tracks

Antioxidants seem to be on a Bill Cosby-like downward spiral from wholesomeness to villainy.

The newest accusations can be found in the Feb. 9, 2015, issue of Cancer Cell, where scientists reported that antioxidants drove both the initiation and the progression of tumors, and that blocking antioxidant pathways could destroy tumor cells.

Because they scavenge free radicals, which induce DNA damage as well as other damage in cells, antioxidants were once thought to protect against cancer.

That idea, however, has not held up to scientific scrutiny.

READ MORE »

Opinion


Partners in Focus